Two Chinese alliances for Amerigen as it pursues branded generics opportunities
This article was originally published in Scrip
The privately held US/Chinese firm Amerigen Pharmaceuticals has joined the ranks of companies building up their branded generics businesses in China through two alliances it hopes will extend its reach in this growing sector.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.